经颈静脉肝内门体分流术术中因素对术后发生肝性脑病的影响

其七; 姚欣; 杨国栋; 秦建平

doi:10.3969/j.issn.1001-5256.2023.08.030

经颈静脉肝内门体分流术术中因素对术后发生肝性脑病的影响

DOI: 10.3969/j.issn.1001-5256.2023.08.030

其七¹,
姚欣²,
杨国栋³,
秦建平^2, , ,

1.
川北医学院临床医学院，四川南充 637000
2.
中国人民解放军西部战区总医院消化内科，成都 610083
3.
川北医学院附属医院消化内科，四川南充 637000

基金项目:

原成都军区总医院基金项目 (2013YG-B009)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：其七负责收集文献，论文撰写；姚欣负责收集文献，参与论文撰写；杨国栋负责论文分析及修改；秦建平负责立题，拟定写作思路，论文修改及最后定稿。

详细信息

通信作者:
秦建平，jpqqing@163.com (ORCID：0000-0001-7834-8830)

计量
- 文章访问数: 277
- HTML全文浏览量: 61
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-04
- 录用日期: 2022-12-05
- 出版日期: 2023-08-20

Research advances in the influence of intraoperative factors during transjugular intrahepatic portosystemic shunt on the development of hepatic encephalopathy

Qi QI¹,
Xin YAO²,
Guodong YANG³,
Jianping QIN^{2
, ,
,}

1.
Clinical Medical College of North Sichuan Medical College, Nanchong, Sichuan 637000, China
2.
Department of Gastroenterology, The General Hospital of Western Theater Command of Chinese People's Liberation Army, Chengdu 610083, China
3.
Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China

Research funding:

Primal Chengdu Military General Hospital Fund Project (2013YG-B009)

More Information

Corresponding author: QIN Jianping, jpqqing@163.com (ORCID: 0000-0001-7834-8830)

摘要

摘要: 肝性脑病(HE)是经颈静脉肝内门体分流术(TIPS)术后常见的并发症之一，影响HE发生的因素复杂，且发病机制尚不十分清楚，如何减少TIPS术后HE的发生，一直是临床关注的问题。有关TIPS操作对术后HE影响方面的研究，国内外均有相关报道，对研究的结果，有些可达成共识意见，有些还存在分歧。本文拟对TIPS术中穿刺门静脉左或右支分流、选择不同内径球囊扩张通道及门静脉压力梯度降低程度等因素对术后HE影响进行综述，为优化TIPS操作，减少术后HE发生提供参考依据。
- 门体分流术, 经颈静脉肝内 /
- 肝性脑病 /
- 肝硬化 /
- 门静脉高压
Abstract: Hepatic encephalopathy (HE) is one of the common complications after transjugular intrahepatic portosystemic shunt (TIPS), with complex influencing factors and an unknown pathogenesis, and how to reduce HE after TIPS has always been a clinical concern. There are reports on the influence of TIPS on postoperative HE both in China and globally, and a consensus has been reached on some of the research results, while there are still controversies over other results. This article reviews the influencing factors for postoperative HE, such as puncture of the left or right portal vein shunt during TIPS, balloon dilatation channels with different inner diameters, and the degree of reduction in hepatic venous pressure gradient, so as to provide a reference for optimizing the operation of TIPS and reducing the onset of postoperative HE.
- Portasystemic Shunt, Transjugular Intrahepatic /
- Hepatic Encephalopathy /
- Liver Cirrhosis /
- Portal Hypertension

HTML全文

参考文献(35)

[1]	TRIPATHI D, STANLEY AJ, HAYES PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension[J]. Gut, 2020, 69(7): 1173-1192. DOI: 10.1136/gutjnl-2019-320221.
[2]	Chinese Society of Emergency Medicine, Interventional Physician Branch of Chinese Medical Doctor Association, Interventional Group of Radiology Society of Chinese Medical Association, et al. Expert consensus on emergency rescue for portal hypertension bleeding (2022)[J]. Chin J Intern Med, 2022, 61(5): 496-506. DOI: 10.3760/cma.j.cn112138-20210922-00653. 中华医学会急诊分会, 中国医师协会介入医师分会, 中华医学会放射学分会介入学组, 等. 门静脉高压出血急救流程专家共识(2022)[J]. 中华内科杂志, 2022, 61(5): 496-506. DOI: 10.3760/cma.j.cn112138-20210922-00653.
[3]	Chinese Medical Doctor Association Branch of Interventional Physicians. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[4]	RIGGIO O, RIDOLA L, ANGELONI S, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial[J]. J Hepatol, 2010, 53(2): 267-272. DOI: 10.1016/j.jhep.2010.02.033.
[5]	PRAKTIKNJO M, ABU-OMAR J, CHANG J, et al. Controlled underdilation using novel VIATORR^® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation[J]. JHEP Rep, 2021, 3(3): 100264. DOI: 10.1016/j.jhepr.2021.100264.
[6]	ZHOU S, YUAN M. The effect of TIPS combined with embolization of large spontaneous portosystemic shunt on postoperative hepatic encephalopathy[J]. Chin Hepatol, 2022, 27(10): 1067-1068. DOI: 10.3969/j.issn.1008-1704.2022.10.005. 周粟, 袁敏. TIPS联合栓塞粗大自发性门体分流道对术后肝性脑病的影响[J]. 肝脏, 2022, 27(10): 1067-1068. DOI: 10.3969/j.issn.1008-1704.2022.10.005.
[7]	LUO X, WANG X, ZHU Y, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm[J]. Cardiovasc Intervent Radiol, 2019, 42(5): 737-743. DOI: 10.1007/s00270-019-02162-4.
[8]	Chinese Society of Gastroenterology and Chinese Society of Hepatology, Chinese Medical Association. Consensus on the diagnosis and treatment of hepatic encephalopathy in China (Chongqing, 2013)[J]. Chin J Dig, 2013, 33(9): 581-592. DOI: 10.3760/cma.j.issn.0254-1432.2013.09.002 中华医学会消化病学分会, 中华医学会肝病学分会. 中国肝性脑病诊治共识意见(2013年, 重庆)[J]. 中华消化杂志, 2013, 33(9): 581-592. DOI: 10.3760/cma.j.issn.0254-1432.2013.09.002.
[9]	FERENCI P, LOCKWOOD A, MULLEN K, et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998[J]. Hepatology, 2002, 35(3): 716-721. DOI: 10.1053/jhep.2002.31250.
[10]	BLEI AT, CÓRDOBA J, Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy[J]. Am J Gastroenterol, 2001, 96(7): 1968-1976. DOI: 10.1111/j.1572-0241.2001.03964.x.
[11]	BAJAJ JS, CORDOBA J, MULLEN KD, et al. Review article: the design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement[J]. Aliment Pharmacol Ther, 2011, 33(7): 739-747. DOI: 10.1111/j.1365-2036.2011.04590.x.
[12]	CASADABAN LC, PARVINIAN A, MINOCHA J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes[J]. Dig Dis Sci, 2015, 60(4): 1059-1066. DOI: 10.1007/s10620-014-3391-0.
[13]	LUO SH, CHU JG, HUANG H, et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J]. World J Gastroenterol, 2019, 25(9): 1088-1099. DOI: 10.3748/wjg.v25.i9.1088.
[14]	MARUYAMA H, OKUGAWA H, ISHIBASHI H, et al. Carbon dioxide-based portography: an alternative to conventional imaging with the use of iodinated contrast medium[J]. J Gastroenterol Hepatol, 2010, 25(6): 1111-1116. DOI: 10.1111/j.1440-1746.2010.06248.x.
[15]	YAO X, HE S, WEI M, et al. Influence of different portal vein branches on hepatic encephalopathy during intrahepatic portal shunt via jugular vein[J]. World J Gastroenterol, 2022, 28(31): 4467-4470. DOI: 10.3748/wjg.v28.i31.4467.
[16]	LJUBICIĆN, DUVNJAK M, ROTKVIĆI, et al. Influence of the degree of liver failure on portal blood flow in patients with liver cirrhosis[J]. Scand J Gastroenterol, 1990, 25(4): 395-400. DOI: 10.3109/00365529009095505.
[17]	YAO X, ZHOU H, TANG SH, et al. Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2020, 36(9): 1970-1974. DOI: 10.3969/j.issn.1001-5256.2020.09.012. 姚欣, 周昊, 汤善宏, 等. 肝硬化门静脉高压患者行经颈静脉肝内门体分流术术中置入Viatorr支架分流门静脉左、右支血流对疗效的影响[J]. 临床肝胆病杂志, 2020, 36(9): 1970-1974. DOI: 10.3969/j.issn.1001-5256.2020.09.012.
[18]	DENG LYY, CHEN Y, YE P, et al. Preliminary analysis of liver - related blood components in portal vein system via TIPS approach[J]. J Intervent Radiol, 2020, 29(6): 608-611. DOI: 10.3969/j.issn.1008-794X.2020.06.018. 邓黎严琰, 陈勇, 叶鹏, 等. 经颈静脉肝内门体分流术初步分析门静脉系统肝脏相关血液成分[J]. 介入放射学杂志, 2020, 29(6): 608-611. DOI: 10.3969/j.issn.1008-794X.2020.06.018.
[19]	TENG D, ZUO H, LIU L, et al. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment[J]. Virol J, 2018, 15(1): 151. DOI: 10.1186/s12985-018-1067-7.
[20]	WANG Q, LV Y, BAI M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol, 2017, 67(3): 508-516. DOI: 10.1016/j.jhep.2017.05.006.
[21]	ROWLEY MW, CHOI M, CHEN S, et al. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt: risk factors and outcomes with revision[J]. Cardiovasc Intervent Radiol, 2018, 41(11): 1765-1772. DOI: 10.1007/s00270-018-1992-2.
[22]	QIN JP, JIANG MD, TANG W, et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center[J]. World J Gastroenterol, 2013, 19(44): 8085-8092. DOI: 10.3748/wjg.v19.i44.8085.
[23]	YAO X, ZHOU H, HUANG S, et al. Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis[J]. World J Clin Cases, 2021, 9(7): 1532-1542. DOI: 10.12998/wjcc.v9.i7.1532.
[24]	CUI J, SMOLINSKI SE, LIU F, et al. Incrementally expandable transjugular intrahepatic portosystemic shunts: single-center experience[J]. AJR Am J Roentgenol, 2018, 210(2): 438-446. DOI: 10.2214/AJR.17.18222.
[25]	QIN JP, TANG SH, JIANG MD, et al. Contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning[J]. World J Gastroenterol, 2015, 21(32): 9623-9629. DOI: 10.3748/wjg.v21.i32.9623.
[26]	SCHEPIS F, VIZZUTTI F, GARCIA-TSAO G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1153-1162. e7. DOI: 10.1016/j.cgh.2018.01.029.
[27]	YAO J, ZUO L, AN G, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal hypertension[J]. J Gastrointestin Liver Dis, 2015, 24(3): 301-307. DOI: 10.15403/jgld.2014.1121.243.yao.
[28]	WAN YM, LI YH, XU ZY, et al. Transjugular intrahepatic portosystemic shunt: the impact of portal venous pressure declines on shunt patency and clinical efficacy[J]. Acad Radiol, 2019, 26(2): 188-195. DOI: 10.1016/j.acra.2018.05.015.
[29]	ELSAID MI, RUSTGI VK. Epidemiology of hepatic encephalopathy[J]. Clin Liver Dis, 2020, 24(2): 157-174. DOI: 10.1016/j.cld.2020.01.001.
[30]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[31]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[32]	BOSCH J. Small diameter shunts should lead to safe expansion of the use of TIPS[J]. J Hepatol, 2021, 74(1): 230-234. DOI: 10.1016/j.jhep.2020.09.018.
[33]	BOYER TD, HASKAL ZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009[J]. Hepatology, 2010, 51(1): 306. DOI: 10.1002/hep.23383.
[34]	BOIKE JR, THORNBURG BG, ASRANI SK, et al. North american practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662. e36. DOI: 10.1016/j.cgh.2021.07.018.
[35]	YAO X, HUANG S, ZHOU H, et al. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2021, 27(30): 5088-5099. DOI: 10.3748/wjg.v27.i30.5088.